title: INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF BREAST CANCER IRIS METASTASIS.
abstract: OBJECTIVE
  To report a case of neovascular and angle closure glaucoma secondary to breast cancer metastatic to the iris that was successfully treated with injections of intravitreal bevacizumab (Avastin) 1.25 mg/0.05 mL.
  
  
  METHODS
  Case report.
  
  
  METHODS
  A 47-year-old woman with metastatic breast cancer presented to The New York Eye Cancer Center with left ocular pain, photosensitivity, vision loss, and multiple iris nodules. Her intraocular pressure was uncontrolled. Gonioscopy revealed neovascularization of the iris and angle; no choroidal neovascularization was noted. Ultrasound biomicroscopy demonstrated tumor invasion of iris stroma with marked anterior uveal thickening and narrowed angles.
  
  
  RESULTS
  Three monthly injections of intravitreal bevacizumab resulted in nearly complete resolution of iris neovascularization, reduction of intraocular pressure, and control of tumor (although a small amount of residual tumor remained).
  
  
  CONCLUSIONS
  Intravitreal anti-vascular endothelial growth factor therapy for breast cancer metastatic to the iris with secondary neovascular glaucoma provided good local control for a limited follow-up period, because the patient died because of systemic complications of her disease.
authors: *The New York Eye Cancer Center, New York, New York; and Departments of †Ophthalmology, ‡Radiation Oncology, and §Medicine, New York University School of Medicine, New York, New York.
authors: Carly J
authors: CJ
authors: Seidman
authors: Paul T
authors: PT
authors: Finger
authors: Joshua S
authors: JS
authors: Silverman
authors: Ruth
authors: R
authors: Oratz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000473:pathology*; D017809:Fatal Outcome; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D015811:Iris Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab